BRAF and melanoma: In short-term viability assays, trametinib at nanomolar concentrations reduced melanoma cell viability in BRAF WT melanoma cell models by approximately 50% (mean maximum effect 54% [46-63%]), whereas in melanoma cells with BRAF mutations, significantly higher reduction rates (p=0.011, Mann-Whitney test) up to 89% (mean maximum effect 64%, [47-89%]) were observed.